{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T01:09:51Z","timestamp":1771463391491,"version":"3.50.1"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vascular Pharmacology"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.vph.2024.107280","type":"journal-article","created":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T01:10:58Z","timestamp":1706836258000},"page":"107280","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Comparative effectiveness of oral therapies targeting the prostacyclin pathway in pulmonary arterial hypertension: A systematic review and network meta-analysis"],"prefix":"10.1016","volume":"154","author":[{"given":"Giovanna","family":"Manzi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco Valerio","family":"Mariani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenico","family":"Filomena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tommaso","family":"Recchioni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Papa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianmarco","family":"Scoccia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Badagliacca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmine Dario","family":"Vizza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vph.2024.107280_bb0005","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1378\/chest.11-1460","article-title":"An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry","volume":"142","author":"Benza","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.vph.2024.107280_bb0010","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1183\/13993003.01032-2015","article-title":"2015 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"46","author":"Gali\u00e9","year":"2015","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.vph.2024.107280_bb0015","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1465-9921-11-12","article-title":"Pharmacotherapy in pulmonary arterial hypertension: a systematic review and meta-analysis","volume":"11","author":"Ryerson","year":"2010","journal-title":"Respir. Res."},{"issue":"138","key":"10.1016\/j.vph.2024.107280_bb0020","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1183\/16000617.0067-2015","article-title":"Recent advances in targeting the prostacyclin pathway in pulmonary arterial hypertension","volume":"24","author":"Lang","year":"2015","journal-title":"Eur Respir Rev."},{"key":"10.1016\/j.vph.2024.107280_bb0025","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/S0735-1097(02)01786-2","article-title":"Effects of Beraprost sodium, an oral prostacyclin analogue in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial","volume":"39","author":"Gali\u00e9","year":"2002","journal-title":"JACC"},{"key":"10.1016\/j.vph.2024.107280_bb0030","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1016\/S0735-1097(03)00463-7","article-title":"Beraprost therapy for pulmonary arterial hypertension","volume":"41","author":"Barst","year":"2003","journal-title":"JACC"},{"key":"10.1016\/j.vph.2024.107280_bb0035","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCULATIONAHA.112.124388","article-title":"Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial","volume":"127","author":"Jing","year":"2013","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.vph.2024.107280_bb0040","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1378\/chest.11-2212","article-title":"Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and\/or phosphodiesterase type 5 inhibitor therapy (The FREEDOM-C Study): a randomized controlled trial","volume":"142","author":"Tapson","year":"2012","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.vph.2024.107280_bb0045","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1378\/chest.12-2875","article-title":"Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study)","volume":"144","author":"Tapson","year":"2013","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.vph.2024.107280_bb0050","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1164\/rccm.201908-1640OC","article-title":"Combination therapy with oral treprostinil for pulmonary arterial hypertension: a double blind placebo-controlled clinical trial","volume":"201","author":"White","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.vph.2024.107280_bb0055","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1056\/NEJMoa1503184","article-title":"Selexipag for the treatment of pulmonary arterial hypertension","volume":"373","author":"Sitbon","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vph.2024.107280_bb0060","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1183\/09031936.00137511","article-title":"Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension","volume":"40","author":"Simonneau","year":"2012","journal-title":"Eur Resp J"},{"key":"10.1016\/j.vph.2024.107280_bb0065","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.chb.2015.09.008","article-title":"Comparative evaluation of the reliability and validity of three data extraction programs: UnGraph, GraphClick, and DigitizeIt","volume":"55","author":"Rakap","year":"2016","journal-title":"Comput. Hum. Behav."},{"key":"10.1016\/j.vph.2024.107280_bb0070","series-title":"Chapter 16: Special topics in statistics. Cochrane Handbook for Systematic Reviews of Interventions. Vol Version 5.1.0 [updated March 2011]","author":"Higgins","year":"2011"},{"issue":"38","key":"10.1016\/j.vph.2024.107280_bb0075","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","article-title":"2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"43","author":"Humbert","year":"2022","journal-title":"Eur. Heart J."},{"issue":"4","key":"10.1016\/j.vph.2024.107280_bb0080","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.healun.2019.12.013","article-title":"Risk assessment in pulmonary arterial hypertension: insights from the GRIPHON study","volume":"39","author":"Sitbon","year":"2020","journal-title":"J. Heart Lung Transplant."},{"key":"10.1016\/j.vph.2024.107280_bb0085","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ccm.2006.11.005","article-title":"Surrogate end points in pulmonary arterial hypertension: assessing the response to therapy","volume":"28","author":"Snow","year":"2007","journal-title":"Clin. Chest Med."},{"key":"10.1016\/j.vph.2024.107280_bb0090","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.healun.2010.11.009","article-title":"Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension","volume":"30","author":"Barst","year":"2011","journal-title":"J. Heart Lung Transplant."},{"issue":"2","key":"10.1016\/j.vph.2024.107280_bb0095","doi-asserted-by":"crossref","DOI":"10.1177\/2045894018770654","article-title":"Dosing characteristics of oral treprostinil in real-world clinical practice","volume":"8","author":"Balasubramanian","year":"2018","journal-title":"Pulm Circ."},{"issue":"2","key":"10.1016\/j.vph.2024.107280_bb0100","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.healun.2016.06.019","article-title":"Transition from parenteral to oral treprostinil in pulmonary arterial hypertension","volume":"36","author":"Chakinala","year":"2017","journal-title":"J. Heart Lung Transplant."},{"issue":"9","key":"10.1016\/j.vph.2024.107280_bb0105","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.healun.2011.03.011","article-title":"Prognostic factors associated with increased survival in patients with pulmonary arterial hypertension treated with subcutaneous treprostinil in randomized, placebo-controlled trials","volume":"30","author":"Benza","year":"2011","journal-title":"J. Heart Lung Transplant."},{"issue":"1","key":"10.1016\/j.vph.2024.107280_bb0110","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1086\/690109","article-title":"Recommendations for the use of oral treprostinil in clinical practice: a Delphi consensus project pulmonary circulation","volume":"7","author":"Rahaghi","year":"2017","journal-title":"Pulm Circ."}],"container-title":["Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189124000053?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189124000053?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T07:06:37Z","timestamp":1724655997000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1537189124000053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":22,"alternative-id":["S1537189124000053"],"URL":"https:\/\/doi.org\/10.1016\/j.vph.2024.107280","relation":{},"ISSN":["1537-1891"],"issn-type":[{"value":"1537-1891","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative effectiveness of oral therapies targeting the prostacyclin pathway in pulmonary arterial hypertension: A systematic review and network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Vascular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vph.2024.107280","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107280"}}